Clinical trials: Neck Cancer
Squamous Cell Carcinoma of the Head and Neck
Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer
This is a randomized, open-label, multi-center, 3-arm, global Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination or MEDI4736 monotherapy versus SoC (EXTREME regimen) in the treatment of…
- Trial name
- KESTREL (NCT02551159)
- Testing
- MEDI4736, Tremelimumab, MEDI4736+Tremelimumab
- Where
- 197 sites in United States, Austria and 21 more
- Volunteers
- 823 people
- Sponsor
- AstraZeneca
Breast Cancer, Brain Cancer
Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R
This phase I dose escalation study will evaluate IGF-Methotrexate conjugate (765IGF-MTX) in patients with advanced, previously treated tumors.
- Conditions
- Breast Cancer, Brain Cancer, Gastrointestinal Cancers, Genitourinary Cancers
- Trial name
- NCT02045368
- Testing
- IGF-Methotrexate conjugate
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- IGF Oncology, LLC
Human Papilloma Virus Infection
Detection of High-Risk HPV in Urine and Cervical Swab Specimen Using HPV Diagnostic Kit (Bio Farma)
This study is a cross-sectional study to evaluate accuracy of high-risk DNA-HPV testing using HPV Diagnostic Kit (Bio Farma) compared to Standard Kit (COBAS® 6800 HPV from Roche Molecular Systems) RT-PCR based in urine and…
- Trial name
- NCT06111911
- Testing
- HPV Diagnostic Kit (Bio Farma)
- Where
- Indonesia
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Uterine Cervical Neoplasms
European Clinical Evaluation of the BD HPV Assay on the BD Viper LT System
The purpose of the study is to compare the results of the Becton Dickinson (BD) Human Papilloma Virus (HPV) Assay on the Viper LT instrument from SurePath media diluted in HPV diluent (pre-quot and/or residual), PreservCyt media…
- Trial name
- NCT01671462
- Testing
- BD HPV assay on Viper LT
- Where
- 2 sites in Denmark, Italy
- Volunteers
- 1,365 people
- Sponsor
- Becton, Dickinson and Company
Lung Cancer, Squamous Cell Carcinoma
An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037
Phase: Exploratory Study Objectives: To collect drug bio-distribution data, begin collection of baseline and tumor/background imaging data, acquire experience to improve study design and the conduct of future studies Design…
- Conditions
- Lung Cancer, Squamous Cell Carcinoma, Head and Neck Cancer, Hepatic Carcinoma
- Trial name
- VM4-037 (NCT00884520)
- Testing
- [F-18] VM4-037
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Siemens Molecular Imaging
HER2-positive, Adenocarcinoma
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.
- Conditions
- HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer
- Trial name
- NCT04660929
- Testing
- CT-0508, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Carisma Therapeutics Inc
Human Papillomavirus, Cervical Intraepithelial Neoplasia
Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females
To evaluate the immune non-inferiority, as measured by antibody responses, of a 2-dose immunization schedule (0, 6 months) of recombinant human papillomavirus virus-like particle vaccine (type 16 and 18 L1 proteins, yeast)…
- Conditions
- Human Papillomavirus, Cervical Intraepithelial Neoplasia, Persistent Infection
- Trial name
- NCT02740777
- Testing
- HPV-16/18 vaccine
- Where
- 2 sites in China
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Melanoma, Non-small Cell Lung Cancer
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
The goal of this clinical research study is to learn how PLX3397 and pembrolizumab work together to affect cancer cells. PLX3397 is designed to target the receptor for CSF1 (CSF1R).
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Gastrointestinal Stromal Tumor (GIST)
- Trial name
- NCT02452424
- Testing
- PLX3397, Pembrolizumab
- Where
- 12 sites in United States
- Volunteers
- 78 people
- Sponsor
- Daiichi Sankyo
Part 1, MELANOMA
A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
Protocol B8011001 is a Phase 1, open-label, multi-center, multiple-dose, dose escalation and expansion, safety, pharmacokinetics (PK), and pharmacodynamics (PD) study of PF-06801591 in previously treated adult patients with…
- Conditions
- Part 1, MELANOMA, SCCHN, OVCA
- Trial name
- NCT02573259
- Testing
- PF-06801591
- Where
- 67 sites in United States, Bulgaria and 5 more
- Volunteers
- 147 people
- Sponsor
- Pfizer
Cervical Intraepithelial Neoplasia
Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) of Cervical Intraepithelial Neoplasia (CIN) Grade 1
The study will examine the effect of HAL vs placebo photodynamic therapy of low-grade cervical precancerous lesions (dysplasia) in women.
- Trial name
- NCT00708942
- Testing
- Hexaminolevulinate (HAL)
- Where
- 5 sites in France, Germany and 1 more
- Volunteers
- 83 people
- Sponsor
- Photocure
Melanoma, Head and Neck Squamous Cell Carcinoma
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts.
- Conditions
- Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer
- Trial name
- NCT04291105
- Testing
- VV1, Cemiplimab
- Where
- 13 sites in United States, Brazil
- Volunteers
- 87 people
- Sponsor
- Vyriad, Inc.
Total Laryngectomy
Short-term Clinical Feasibility of the New Provox Vega 22.5 Voice Prosthesis
The purpose of this study is to investigate the performance of a new voice prosthesis in comparison with the Provox2 and the Provox ActiValve voice prosthesis in 15 laryngectomized patients.
- Trial name
- NCT00743262
- Testing
- Provox voice prosthesis
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Atos Medical AB
Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
A multicenter, single-arm, first-in-human study to investigate the safety, pharmacokinetics, and preliminary antitumor activity of PLX-61639 in participants with locally advanced or metastatic, relapsed/refractory…
- Conditions
- Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- NCT07284186
- Testing
- PLX-61639
- Where
- 10 sites in United States
- Volunteers
- 155 people
- Sponsor
- Plexium, Inc.
Colorectal Cancer, Triple Negative Breast Cancer
Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour
This clinical trial is an open-label, single-centre, dose escalation, phase I study designed to investigate the safety and tolerability of Haploidentical / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted Gamma Delta…
- Conditions
- Colorectal Cancer, Triple Negative Breast Cancer, Sarcoma, Nasopharyngeal Carcinoma
- Trial name
- NCT04107142
- Testing
- Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell
- Where
- Malaysia
- Volunteers
- 10 people
- Sponsor
- CytoMed Therapeutics Pte Ltd
Solid Tumor, Head and Neck Cancer
Ixovex-1 Single Agent and Combination Therapy
This is an open-label, dose de-escalating, non-randomised, multi-centre phase I/II study to determine safety and efficacy of the oncolytic virus, Ixovex-1 administered by intratumoural (IT) injection.
- Trial name
- IXACT (NCT06549946)
- Testing
- Ixovex-1, Pembrolizumab
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Psivac Ltd
Carcinoma, Squamous Cell
An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
The aim of this prospective, observational, multicenter, post-marketing study is to evaluate the safety and efficacy of Cetuximab (Erbitux) in combination with platinum based chemotherapy, in the first line therapy of recurrent/…
- Trial name
- NCT01142869
- Testing
- Cetuximab
- Where
- 28 sites in India
- Volunteers
- 133 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Cervical Persistent High Risk HPV Infection, Cervical Intraepithelial Neoplasia
Aminolaevulinic Acid Photodynamic Therapy of Cervical Persistent HPV Infection and Cervical Neoplasia
The study will examine the effect of aminolaevulinic acid (ALA) photodynamic therapy (PDT) of cervical precancerous lesions in women.
- Trial name
- NCT02304770
- Testing
- Aminolaevulinic acid photodynamic therapy
- Where
- 4 sites in China
- Volunteers
- 73 people
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
NSCLC, HNSCC
Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC
Evaluate the safety and efficacy of the combination of eftilagimod alpha with pembrolizumab in non-small cell lung carcinoma and head and neck carcinoma patients.
- Trial name
- TACTI-002 (NCT03625323)
- Testing
- eftilagimod alpha, pembrolizumab (KEYTRUDA®)
- Where
- United States
- Volunteers
- 187 people
- Sponsor
- Immutep S.A.S.
Neoplasms, Head and Neck
Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer
This is a phase II study comparing the effects of lapatinib versus placebo when administered concurrently with cisplatin and radiotherapy followed by 1 year monotherapy with lapatinib or placebo.
- Trial name
- NCT00387127
- Testing
- Lapatinib oral tablets, radiotherapy, cisplatin chemotherapy
- Where
- 30 sites in United States, Canada and 7 more
- Volunteers
- 67 people
- Sponsor
- GlaxoSmithKline
Esophageal Cancer, Lung Cancer
Case Analysis on Real Life Incidence of Photodynamic Therapy (PDT) Safety Outcomes
Three main adverse reactions, namely photosensitivity (reaction that is similar to sunburn), oesophageal stenosis (narrowing or closure of the food pipe), perforation of the treated area (a tear or puncture of the tissue), have…
- Conditions
- Esophageal Cancer, Lung Cancer, Barrett's Esophagus
- Trial name
- CALIPSO (NCT01203163)
- Sponsor
- Pinnacle Biologics Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.